Maxim Group Reiterates “Hold” Rating for Aclarion (NASDAQ:ACON)

Maxim Group restated their hold rating on shares of Aclarion (NASDAQ:ACON) in a report issued on Friday,Benzinga reports.

Separately, Ascendiant Capital Markets decreased their price target on Aclarion from $1.50 to $1.30 and set a “buy” rating for the company in a research report on Wednesday, November 27th.

Aclarion Price Performance

ACON opened at $0.11 on Friday. The business has a fifty day simple moving average of $0.18 and a 200-day simple moving average of $0.23. Aclarion has a fifty-two week low of $0.10 and a fifty-two week high of $7.40.

Aclarion Company Profile

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.